HighlightsIntestinal angiosarcoma is a diagnostic challenge due to non-specific clinical presentation and rarity.The diagnosis of intestinal angiosarcoma must be considered in a patient with gastrointestinal bleeding and history of radiation therapy.The adjuvant therapy to intestinal angiosarcoma is not well established.
Borderline ovarian tumors (BOTs) are neoplasms with benign and malignant characteristics, affecting young women in childbearing age. Finding incidental adnexal mass in pregnancy is more common with the use of ultrasound, incidence is about 2% to 10% of pregnancies. A great majority of adnexal masses excised during pregnancy are in fact BOTs. Treatment varies depending of gestational age: before 24 gestational week is usually conservative and surgical staging. Radical management is reserved to patients with suspected malignancy and satisfied parity. A 38-years-old woman presented to external consultation in a rural hospital with 36 gestational weeks of her fourth pregnancy, without antenatal control and asymptomatic. Obstetric ultrasound reported: right ovarian tumor with cystic and solid areas. Laboratory data were normal. She underwent elective cesarean and exploratory laparotomy, surgical findings were: a term female baby with no obstetric complications and a right ovarian tumor with trans-operatory report of mucinous epithelial cells with atypia, suggestive of ovarian borderline tumor. Based on this, a hysterectomy with bilateral oophorectomy was performed. No complications were reported. Post-operatory evolution was normal. Definitive histopathological study reported a borderline ovarian tumor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.